Sen. Elizabeth Warren (D-Mass.) and Sen. Elissa Slotkin (D-Mich.) demanded an investigation Wednesday into potential conflicts of interest concerning Trump administration officials David Sacks and Steve Witkoff, and their association with the World Liberty Financial cryptocurrency venture.
UAE AI Deal Under Scanner
In a letter sent to to Duane Townsend, the acting inspector general of the Commerce Department, Eric Ueland, the acting director of the Office of Government Ethics and Arne Baker, acting inspector general at the State Department, the lawmakers requested a probe into the roles that Sacks, Trump’s AI and Crypto Czar, and Witkoff, U.S. Special Envoy to the Middle East, might have played in advocating for the U.S. to “sell sensitive national security technology” to the United Arab Emirates.
“According to reports, Mr. Witkoff and Mr. Sacks both played key roles in the White House's decision to relax national security restrictions on the shipment of advanced AI systems to the UAE," the senators wrote, citing a New York Times report.
See Also: Forget Stocks—Bitcoin Could Crush Everything In 2025 And Beyond, Top Investor Says
A World Liberty Financial Link?
The Senators are also interested in determining the extent to which Sacks and Witkoff could financially gain from these deals.
“These overlapping ties mean both men stand to profit from government decisions they helped shape,” the letter read.
Notably, World Liberty Financial’s co-founders include Trump’s three sons, Eric Trump, Donald Trump Jr and Barron Trump.
Benzinga has reached out to the White House and David Sacks and is awaiting their response.
Warren Steps Up Attack
Warren previously labeled the Trump-backed stablecoin USD1 as a potential threat to national security and a conduit for corruption.
"Trump’s stablecoin is shady and a national security risk," she said. "He’s cashing in on foreign crypto deals—and weakening guardrails that protect our advanced technology."
Read Next:
Photo Courtesy: Brian Jason on Shutterstock.com
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.